(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 September 2021 (30.09.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/195163 A1

(51) International Patent Classification:
A61K 9/00 (2006.01) *A61K 47/10* (2017.01)
A61K 47/34 (2017.01)

(21) International Application Number:
PCT/US2021/023806

(22) International Filing Date:
24 March 2021 (24.03.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/994,391 25 March 2020 (25.03.2020) US
PCT/US2020/029827
24 April 2020 (24.04.2020) US
63/106,276 27 October 2020 (27.10.2020) US
63/148,463 11 February 2021 (11.02.2021) US

(71) Applicant: **OCULAR THERAPEUTIX, INC.** [US/US]; 24 Crosby Drive, Bedford, MA 01730 (US).

(72) Inventors: **BLIZZARD, Charles, D.**; 6 Danbury Road, Nashua, NH 03064 (US). **DRISCOLL, Arthur**; 14 Grey Coach Lane, Reading, MA 01867 (US). **EL-HAYEK, Rami**; 42 Concord Avenue, Norwood, MA 02062 (US). **GOLDSTEIN, Michael**; 3 Hurlbut Street, Cambridge, MA 02138 (US). **IACONA, Joseph**; 90 School Street, Apt. 3, Somerville, MA 02143 (US). **JARRETT, Peter**; 20 2nd Avenue, Apt. 218, Burlington, MA 01803 (US). **JARRETT, Timothy, S.**; 200 West Brookline Street, Boston, MA 02118 (US). **KAHN, Erica**; 271 Mt. Auburn Street, Cambridge, MA 02138 (US). **LATTRELL, Zachary**; 10 Cutting Drive, Newburyport, MA 01950 (US).

(74) Agent: **PARADISO, Robert, J.** et al.; Lowenstein Sandler LLP, One Lowenstein Drive, Roseland, NJ 07068 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: OCULAR IMPLANT CONTAINING A TYROSINE KINASE INHIBITOR

(57) Abstract: The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.




FIGURE 1

WO 2021/195163 A1

[Continued on next page]

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*